

# Carbapenem resistant *Klebsiella pneumoniae*- Market Insights, Epidemiology and Market Forecast 2028

<https://marketpublishers.com/r/C8F8AA744EDEN.html>

Date: June 2019

Pages: 87

Price: US\$ 5,980.00 (Single User License)

ID: C8F8AA744EDEN

## Abstracts

### Report Summary

'Carbapenem resistant *Klebsiella pneumoniae*- Market Insights, Epidemiology and Market Forecast 2028' report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2016-2028.

Market Segment by Countries, covering?

United States

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Japan

Study Period: 2016-2028

Carbapenem resistant *Klebsiella pneumoniae* Understanding and Treatment Algorithm  
The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Carbapenem resistant *Klebsiella pneumoniae* in the US, Europe, and Japan are also provided in the report.

Carbapenem resistant *Klebsiella pneumoniae* Epidemiology

This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies,

survey reports as well as KOL's views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

#### Carbapenem resistant Klebsiella pneumonia Product Profiles & Analysis

This part of the Carbapenem resistant Klebsiella pneumonia report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

#### Carbapenem resistant Klebsiella pneumonia Market Outlook

The Carbapenem resistant Klebsiella pneumonia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders . The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.

#### Carbapenem resistant Klebsiella pneumonia Market Share by Therapies

This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

#### Carbapenem resistant Klebsiella pneumonia Report Insights

Patient Population in Carbapenem resistant Klebsiella pneumonia

Therapeutic Approaches in Carbapenem resistant Klebsiella pneumonia

Carbapenem resistant Klebsiella pneumonia Pipeline Analysis

Carbapenem resistant Klebsiella pneumonia Market Size and Trends  
Carbapenem resistant Klebsiella pneumonia Market Opportunities  
Impact of upcoming Therapies in Carbapenem resistant Klebsiella pneumonia

Carbapenem resistant Klebsiella pneumonia Report Key Strengths  
10 Year Forecast  
7MM Coverage  
Epidemiology Segmentation  
Drugs Uptake  
Highly Analyzed Market  
Key Cross Competition

Carbapenem resistant Klebsiella pneumonia Report Assessment  
Current Treatment Practices in Carbapenem resistant Klebsiella pneumonia  
Unmet Needs in Carbapenem resistant Klebsiella pneumonia  
Detailed Carbapenem resistant Klebsiella pneumonia Pipeline Product Profiles  
Market Attractiveness  
Market Drivers and Barriers

Key Benefits

This report will help to develop Business Strategies by understanding the trends shaping and driving the Carbapenem resistant Klebsiella pneumonia market  
Organize sales and marketing efforts by identifying the best opportunities for Carbapenem resistant Klebsiella pneumonia market  
To understand the future market competition in the Carbapenem resistant Klebsiella pneumonia market.

**Note:** We understand the needs of the rapidly changing market and is helping the client by providing the most up to date Report. It usually takes 4-5 days to deliver this kind of Report. The report coverage will depend on the availability of the data.

Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

## Contents

### 1 KEY INSIGHTS

### 2 CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIA MARKET OVERVIEW AT A GLANCE

2.1 Market Share (%) Distribution of Carbapenem resistant Klebsiella pneumonia in 2018

2.2 Market Share (%) Distribution of Carbapenem resistant Klebsiella pneumonia in 2028

### 3 CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIA: DISEASE BACKGROUND AND OVERVIEW

3.1 Introduction

3.2 Symptoms

3.3 Etiology

3.4 Risk Factor

3.5 Pathophysiology

3.6 Diagnosis

3.7 Treatment

### 4 EPIDEMIOLOGY AND PATIENT POPULATION

4.1. Key Findings

4.2. Total Prevalent/ Incident Patient Population of Carbapenem resistant Klebsiella pneumonia in 7MM

4.3. Total Prevalent Patient Population of Carbapenem resistant Klebsiella pneumonia in 7MM – By Countries

### 5 EPIDEMIOLOGY OF CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIA BY COUNTRIES (2016-2028)

5.1 United States- Epidemiology (2016-2028)

5.1.1 Assumptions and Rationale

5.1.2 Prevalent/Incident Cases of Carbapenem resistant Klebsiella pneumonia in the United States

5.1.3 Sub-Type Specific cases of Carbapenem resistant Klebsiella pneumonia in the

## United States

5.1.4 Sex- Specific Cases of Carbapenem resistant Klebsiella pneumonia in the United States

5.1.5 Diagnosed Cases of Carbapenem resistant Klebsiella pneumonia in the United States

5.1.6 Treatable Cases of Carbapenem resistant Klebsiella pneumonia in the United States

## 5.2 EU5 Countries

### 5.2.1 Germany

5.2.1.1 Assumptions and Rationale

5.2.1.2 Prevalent/Incident Cases of the of Carbapenem resistant Klebsiella pneumonia in the Germany

5.2.1.3 Sub-Type Specific cases of Carbapenem resistant Klebsiella pneumonia in the Germany

5.2.1.4 Sex- Specific Cases of the Carbapenem resistant Klebsiella pneumonia in the Germany

5.2.1.5 Diagnosed Cases of the Carbapenem resistant Klebsiella pneumonia in the Germany

5.2.1.6 Treatable Cases of the Carbapenem resistant Klebsiella pneumonia

### 5.2.2 France

5.2.2.1 Assumptions and Rationale

5.2.2.2 Prevalent/Incident Cases of the of Carbapenem resistant Klebsiella pneumonia in the France

5.2.2.3 Sub-Type Specific cases of Carbapenem resistant Klebsiella pneumonia in the France

5.2.2.4 Sex- Specific Cases of the Carbapenem resistant Klebsiella pneumonia in the France

5.2.2.5 Diagnosed Cases of the Carbapenem resistant Klebsiella pneumonia in the France

5.2.2.6 Treatable Cases of the Carbapenem resistant Klebsiella pneumonia

### 5.2.3 Italy

5.2.3.1 Assumptions and Rationale

5.2.3.2 Prevalent/Incident Cases of the of Carbapenem resistant Klebsiella pneumonia in the Italy

5.2.3.3 Sub-Type Specific cases of Carbapenem resistant Klebsiella pneumonia in the Italy

5.2.3.4 Sex- Specific Cases of the Carbapenem resistant Klebsiella pneumonia in the Italy

5.2.3.5 Diagnosed Cases of the Carbapenem resistant Klebsiella pneumonia in the

## Italy

5.2.3.6 Treatable Cases of the Carbapenem resistant Klebsiella pneumonia

## 5.2.4 Spain

5.2.4.1 Assumptions and Rationale

5.2.4.2 Prevalent/Incident Cases of the of Carbapenem resistant Klebsiella pneumonia in the Spain

5.2.4.3 Sub-Type Specific cases of Carbapenem resistant Klebsiella pneumonia in the Spain

5.2.4.4 Sex- Specific Cases of the Carbapenem resistant Klebsiella pneumonia in the Spain

5.2.4.5 Diagnosed Cases of the Carbapenem resistant Klebsiella pneumonia in the Spain

5.2.4.6 Treatable Cases of the Carbapenem resistant Klebsiella pneumonia

## 5.2.5 United Kingdom

5.2.5.1 Assumptions and Rationale

5.2.5.2 Prevalent/Incident Cases of the of Carbapenem resistant Klebsiella pneumonia in the United Kingdom

5.2.5.3 Sub-Type Specific cases of Carbapenem resistant Klebsiella pneumonia in the United Kingdom

5.2.5.4 Sex- Specific Cases of the Carbapenem resistant Klebsiella pneumonia in the United Kingdom

5.2.5.5 Diagnosed Cases of the Carbapenem resistant Klebsiella pneumonia in the United Kingdom

5.2.5.6 Treatable Cases of the Carbapenem resistant Klebsiella pneumonia

## 5.3 Japan

5.3.1 Assumptions and Rationale

5.3.2 Prevalent/Incident Cases of the of Carbapenem resistant Klebsiella pneumonia in the Japan

5.3.3 Sub-Type Specific cases of Carbapenem resistant Klebsiella pneumonia in the Japan

5.3.4 Sex- Specific Cases of the Carbapenem resistant Klebsiella pneumonia in the Japan

5.3.5 Diagnosed Cases of the Carbapenem resistant Klebsiella pneumonia in the Japan

5.3.6 Treatable Cases of the Carbapenem resistant Klebsiella pneumonia

## **6 CURRENT TREATMENT & MEDICAL PRACTICES**

### 6.1 Treatment Algorithm

## 6.2 Treatment Guidelines

## 7 UNMET NEEDS

## 8 MARKETED PRODUCT

### 8.1 Drug A: Company

8.1.1 Drug Description

8.1.2 Mechanism of Action

8.1.3 Clinical Trials Details

8.1.4 Advantages & Disadvantages

8.1.5 Safety and Efficacy

8.1.6 Product Profile

### 8.2 Drug B: Company

8.2.1 Drug Description

8.2.2 Mechanism of Action

8.2.3 Clinical Trials Details

8.2.4 Advantages & Disadvantages

8.2.5 Safety and Efficacy

8.2.6 Product Profile

### 8.3 Drug C: Company

8.3.1 Drug Description

8.3.2 Mechanism of Action

8.3.3 Clinical Trials Details

8.3.4 Advantages & Disadvantages

8.3.5 Safety and Efficacy

8.3.6 Product Profile

### 8.4 Drug D: Company

8.4.1 Drug Description

8.4.2 Mechanism of Action

8.4.3 Clinical Trials Details

8.4.4 Advantages & Disadvantages

8.4.5 Safety and Efficacy

8.4.6 Product Profile

### 8.5 Drug E: Company

8.5.1 Drug Description

8.5.2 Mechanism of Action

8.5.3 Clinical Trials Details

8.5.4 Advantages & Disadvantages

8.5.5 Safety and Efficacy

8.5.6 Product Profile

8.6 : Company

8.6.1 Drug Description

8.6.2 Mechanism of Action

8.6.3 Clinical Trials Details

8.6.4 Advantages & Disadvantages

8.6.5 Safety and Efficacy

8.6.6 Product Profile

8.7 : Company

8.7.1 Drug Description

8.7.2 Mechanism of Action

8.7.3 Clinical Trials Details

8.7.4 Advantages & Disadvantages

8.7.5 Safety and Efficacy

8.7.6 Product Profile

8.8 : Company

8.8.1 Drug Description

8.8.2 Mechanism of Action

8.8.3 Clinical Trials Details

8.8.4 Advantages & Disadvantages

8.8.5 Safety and Efficacy

8.8.6 Product Profile

## **9 EMERGING DRUGS**

9.1 Key Cross Competition

9.2 Emerging company

9.2.1 Emerging Drug A: Company

9.2.1.1 Other Development Activities

9.2.1.2 Clinical Development

9.2.1.3 Clinical Trials Information

9.2.1.4 Safety and Efficacy

9.2.1.5 Advantages and Disadvantages

9.2.1.6 Product Profile

9.2.2 Emerging Drug B: Company

9.2.2.1 Other Development Activities

9.2.2.2 Clinical Development

9.2.2.3 Clinical Trials Information



- 9.2.2.4 Safety and Efficacy
- 9.2.2.5 Advantages and Disadvantages
- 9.2.2.6 Product Profile
- 9.2.3 Emerging Drug C: Company
  - 9.2.3.1 Other Development Activities
  - 9.2.3.2 Clinical Development
  - 9.2.3.3 Clinical Trials Information
  - 9.2.3.4 Safety and Efficacy
  - 9.2.3.5 Advantages and Disadvantages
  - 9.2.3.6 Product Profile
- 9.2.4 Emerging Drug D: Company
  - 9.2.4.1 Other Development Activities
  - 9.2.4.2 Clinical Development
  - 9.2.4.3 Clinical Trials Information
  - 9.2.4.4 Safety and Efficacy
  - 9.2.4.5 Advantages and Disadvantages
  - 9.2.4.6 Product Profile
- 9.2.5 Emerging Drug E: Company
  - 9.2.5.1 Other Development Activities
  - 9.2.5.2 Clinical Development
  - 9.2.5.3 Clinical Trials Information
  - 9.2.5.4 Safety and Efficacy
  - 9.2.5.5 Advantages and Disadvantages
  - 9.2.5.6 Product Profile

## **10 7MM MARKET ANALYSIS**

- 10.1 7MM Market Size of Carbapenem resistant Klebsiella pneumonia
- 10.2 7MM Percentage Share of Drugs Marketed for Carbapenem resistant Klebsiella pneumonia
- 10.3 7MM Market Sales of Carbapenem resistant Klebsiella pneumonia by Products

## **11 THE UNITED STATES MARKET OUTLOOK**

- 11.1 Market Size of Carbapenem resistant Klebsiella pneumonia in United States
- 11.2 Percentage Share of Drugs Marketed for Carbapenem resistant Klebsiella pneumonia in United States
- 11.3 Market Sales of Carbapenem resistant Klebsiella pneumonia by Products in United States

## 11.4 Analysis of Upcoming Therapies and Impact on the Market

## 12 EU5 COUNTRIES MARKET OUTLOOK

### 12.1 Market Size of Carbapenem resistant Klebsiella pneumonia in EU5

### 12.2 Market Size of Carbapenem resistant Klebsiella pneumonia in Germany

#### 12.2.1 Market Size of Carbapenem resistant Klebsiella pneumonia in Germany

#### 12.2.2 Percentage Share of Drugs Marketed for Carbapenem resistant Klebsiella pneumonia in Germany

#### 12.2.3 Market Sales of Carbapenem resistant Klebsiella pneumonia by Products in Germany

#### 12.2.4 Analysis of Upcoming Therapies and Impact on the Market

### 12.3 Market Size of Carbapenem resistant Klebsiella pneumonia in France

#### 12.3.1 Market Size of Carbapenem resistant Klebsiella pneumonia in France

#### 12.3.2 Percentage Share of Drugs Marketed for Carbapenem resistant Klebsiella pneumonia in France

#### 12.3.3 Market Sales of Carbapenem resistant Klebsiella pneumonia by Products in France

#### 12.3.4 Analysis of Upcoming Therapies and Impact on the Market

### 12.4 Market Size of Carbapenem resistant Klebsiella pneumonia in Italy

#### 12.4.1 Market Size of Carbapenem resistant Klebsiella pneumonia in Italy

#### 12.4.2 Percentage Share of Drugs Marketed for Carbapenem resistant Klebsiella pneumonia in Italy

#### 12.4.3 Market Sales of Carbapenem resistant Klebsiella pneumonia by Products in Italy

#### 12.4.4 Analysis of Upcoming Therapies and Impact on the Market

### 12.5 Market Size of Carbapenem resistant Klebsiella pneumonia in Spain

#### 12.5.1 Market Size of Carbapenem resistant Klebsiella pneumonia in Spain

#### 12.5.2 Percentage Share of Drugs Marketed for Carbapenem resistant Klebsiella pneumonia in Spain

#### 12.5.3 Market Sales of Carbapenem resistant Klebsiella pneumonia by Products in Spain

#### 12.5.4 Analysis of Upcoming Therapies and Impact on the Market

### 12.6 Market Size of Carbapenem resistant Klebsiella pneumonia in United Kingdom

#### 12.6.1 Market Size of Carbapenem resistant Klebsiella pneumonia in United Kingdom

#### 12.6.2 Percentage Share of Drugs Marketed for Carbapenem resistant Klebsiella pneumonia in United Kingdom

#### 12.6.3 Market Sales of Carbapenem resistant Klebsiella pneumonia by Products in United Kingdom

12.6.4 Analysis of Upcoming Therapies and Impact on the Market

## **13 THE JAPAN MARKET OUTLOOK**

13.1 Market Size of Carbapenem resistant Klebsiella pneumonia in Japan

13.2 Percentage Share of Drugs Marketed for Carbapenem resistant Klebsiella pneumonia in Japan

13.3 Market Sales of Carbapenem resistant Klebsiella pneumonia by Products in Japan

13.4 Analysis of Upcoming Therapies and Impact on the Market

## **14 COST ANALYSIS OF CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIA**

## **15 GENERIC COMPETITION IN CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIA MARKET**

## **16 MARKET DRIVERS**

## **17 MARKET BARRIERS**

## **18 REPORT METHODOLOGY**

18.1 Methodology/Research Approach

18.2 Data Source

18.2.1 Secondary Sources

18.2.2 Primary Sources

## I would like to order

Product name: Carbapenem resistant Klebsiella pneumonia- Market Insights, Epidemiology and Market Forecast 2028

Product link: <https://marketpublishers.com/r/C8F8AA744EDEN.html>

Price: US\$ 5,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C8F8AA744EDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

